Ozempic Weight Loss: Clinical Evidence & Individual Factors

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) produced average weight loss of 5-15% body weight over 68 weeks in SUSTAIN trials, though individual results ranged from minimal to 20%+ reduction. This variation reflects differences in genetics, metabolism, adherence, and lifestyle factors that deserve clinical consideration before and during treatment.

Weight loss outcomes with GLP-1 medications depend on far more than the drug alone. Your individual metabolic profile, genetic predispositions in appetite-regulation pathways, baseline body composition, and behavioral factors all influence whether you'll experience modest or substantial results. PlexusDx supports precision-wellness approaches by helping patients understand their unique biological context.

Clinical Trial Data: What the Evidence Actually Shows

The SUSTAIN-7 trial demonstrated 13.5% average weight loss with 1.0 mg Ozempic weekly in people with type 2 diabetes, while non-diabetic STEP trials showed 9.2-10.9% reductions over 68 weeks. Importantly, 35-50% of participants achieved 10% or greater weight loss, while others saw 5% or less despite consistent dosing.

Weight loss typically occurs in phases: rapid initial loss (weeks 4-16) due to reduced appetite and calorie intake, followed by slower steady decline. Plateau periods are common and do not indicate treatment failure—they reflect metabolic adaptation and the body's energy-balance homeostasis mechanisms.

Key Factors Influencing Your Individual Weight Loss Response

Multiple interconnected variables determine whether you'll achieve 5% or 15%+ weight loss: baseline metabolic rate, insulin sensitivity status, adherence to the injection schedule, dietary habits, physical activity level, sleep quality, and genetic variation in GLP-1 receptor sensitivity. No single factor dominates—they work together to shape outcomes.

Factor Category	Impact on Weight Loss	Clinical Relevance
GLP-1 Receptor Sensitivity (genetic)	May influence appetite suppression magnitude and duration	Genetic variants (e.g., GLP1R rs6923761) create baseline pathway predisposition
Insulin Resistance Status	Higher baseline insulin resistance may predict greater initial weight loss	Biomarkers: HOMA-IR, fasting insulin, glucose levels at baseline
Dietary Adherence & Calorie Deficit	Accounts for 60-70% of weight loss variance across individuals	Consistent 500-750 kcal daily deficit amplifies medication benefit
Physical Activity & Muscle Preservation	Supports fat-specific loss vs. lean mass loss; enhances sustainability	Even modest activity (150 min/week) improves long-term outcomes

Genetic Predispositions in Appetite and Metabolism Pathways

Variants in genes encoding GLP-1 receptors (GLP1R), glucose-dependent insulinotropic peptide receptors (GIPR), and metabolic regulators (FTO, MC4R) influence how effectively semaglutide suppresses appetite and promotes weight loss. These predispositions do not determine your outcome but may help contextualize expected response patterns within a clinical conversation.

For example, individuals with specific FTO rs9939609 genotypes show greater baseline appetite drive and may experience more pronounced appetite suppression with GLP-1 therapy—though lifestyle factors often have equal or greater impact. Understanding your genetic architecture supports realistic goal-setting and provider collaboration on medication selection and dosing strategy.

Safety, Eligibility, and When Ozempic Requires Medical Supervision

Ozempic is approved for type 2 diabetes management and carries FDA labeling; off-label weight-loss use requires individualized provider assessment. Contraindications include personal history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe pancreatitis, or severe gastroparesis. Pregnancy is contraindicated; reliable contraception is essential during treatment.

Common side effects—nausea, vomiting, constipation, diarrhea—often improve after 4-8 weeks but affect adherence and may limit weight loss if dosing is interrupted. Your provider should assess baseline gastrointestinal function, kidney/liver status, and medication interactions before initiating therapy. Regular follow-up ensures you tolerate the medication and achieve safe, sustainable weight reduction.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in GLP-1 receptor (GLP1R rs6923761), GIPR (rs1800437), FTO (rs9939609), and melanocortin-4 receptor (MC4R rs17782313) pathways. These genetic insights may help provide context for individual appetite-regulation biology and metabolic predisposition—supporting more informed provider conversations about whether GLP-1 therapy aligns with your biological profile and realistic weight loss expectations.

The test reveals predispositions in peptide genetic pathways, not exact medication response or guaranteed outcomes. A result showing higher-risk FTO variants or GLP1R sensitivity markers does not predict how much weight you will lose or whether a specific medication will work—only that your baseline pathway activity may influence appetite and metabolic regulation. Clinical outcomes depend far more on adherence, lifestyle, and individual physiology.

Understanding your genetic context can support a more personalized conversation with your healthcare provider about medication selection (semaglutide vs. tirzepatide vs. other options), expected timelines, potential side effect patterns, and whether compounded or branded formulations best fit your clinical needs and financial situation. This precision-wellness approach helps move beyond one-size-fits-all treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.